Replies to post #250 on Equity Field Notes from temporal sources

[DanWebzster]

ACRX may benefit from legislation that allows DOD to use medical products that are unapproved by the FDA.

Rather than cede control of a group of treatments to another agency, FDA has agreed to expedite development and review of treatments upon Secretary of Defense request.

As a result, DSUVIA is in a much stronger position for approval for its 11/3/18 PDUFA.

Watch for an October Adcom.